SEC Comment Letter 0000000000-24-001719 to Meihua International Medical Technologies Co., Ltd. (MHUA) (CIK 0001835615) (MHUAF)

Meihua International Medical Technologies Co., Ltd. (MHUA) (CIK 0001835615)
Date: Feb. 13, 2024 · CIK: 0001835615 · Accession: 0000000000-24-001719

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-276882

Date

February 13, 2024

Author

Not clearly detected

Form

UPLOAD

Company

Meihua International Medical Technologies Co., Ltd. (MHUA) (CIK 0001835615)

Letter

United States securities and exchange commission logo February 13, 2024 Xin Wang Chief Executive Officer Meihua International Medical Technologies Co., Ltd. 88 Tongda Road, Touqiao Town Guangling District, Yangzhou, 225000 People’s Republic of China Re:Meihua International Medical Technologies Co., Ltd. Registration Statement on Form F-1 Filed February 6, 2024 File No. 333-276882 Dear Xin Wang: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Juan Grana at 202-551-6034 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Megan J. Penick, Esq.

Show Raw Text

United States securities and exchange commission logo
February 13, 2024
Xin Wang
Chief Executive Officer
Meihua International Medical Technologies Co., Ltd.
88 Tongda Road, Touqiao Town
Guangling District, Yangzhou, 225000
People’s Republic of China
Re:Meihua International Medical Technologies Co., Ltd.
Registration Statement on Form F-1
Filed February 6, 2024
File No. 333-276882
Dear Xin Wang:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Juan Grana at 202-551-6034 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       Megan J. Penick, Esq.

SecProbe.io